Author:
Manzaneque Alba,Chaguaceda Cristian,Mensa Mireia,Bastida Carla,Creus-Baró Natàlia
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology,Toxicology,Pharmacy
Reference10 articles.
1. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumors: recommendations of an international expert panel. Ann Oncol. 2008;19(3):420–32.
2. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, De Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132–9.
3. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, doubleblind study. Lancet. 2011;377(9768):813–22.
4. European Medicines Agency. Xgeva (denosumab) summary of product characteristics.
http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002173/WC500110381.pdf
. Accessed 10 Jan 2016.
5. Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer. 2016;24(1):447–55.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献